ANTH Anthera Pharmaceuticals, Inc.

0.41
+0  (2%)
Previous Close 0.41
Open 0.40
Price To book 4.86
Market Cap 20.99M
Shares 50,609,000
Volume 2,195,058
Short Ratio 4.01
Av. Daily Volume 2,608,230

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due end of 2017 or early 2018.
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 2 primary endpoint not met
Blisibimod
IgA nephropathy
Top-line data released December 27, 2016 - missed primary endpoint.
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3 trial did not meet endpoints - November 10, 2016.
Blisibimod
Lupus

Latest News

  1. Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
  2. ANTHERA PHARMACEUTICALS INC Financials
  3. Anthera Pharmaceuticals, Inc. :ANTH-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
  4. Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%
  5. ANTH INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017
  6. Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%
  7. Implied Volatility Surging for Anthera (ANTH) Stock Options
  8. Shire's (SHPG) Cinryze Label Expanded for Pediatric Use
  9. Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA
  10. Guess, Anthera Pharmaceuticals Dive into Thursday’s 52-Week Low Club
  11. ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
  12. Inovio (INO) Q4 Loss Wider than Expected; Shares Decline
  13. SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Anthera Pharmaceuticals, Inc. (ANTH) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
  14. Valeant, JC Penney Plunge Into Tuesday’s 52-Week Low Club
  15. ANTH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017
  16. Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
  17. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
  18. New Strong Buy Stocks for March 8th
  19. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc.
  20. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Anthera Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit